Syngene International Ltd

Syngene Intl. Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Syngene International Ltd

₹ 471 1.03%
19 May 4:01 p.m.
syngeneintl.com BSE: 539268 NSE: SYNGENE
About

Syngene (established in 1993) as a Biocon subsidiary is India's first Contract Research Organization (CRO) which expanded later to be an integrated service provider offering end-to-end drug discovery, development, and manufacturing services on a single platform (CRAMS). Total research & manufacturing infrastructure for the company is spread across 1.9 million square feet across locations. [1]

Key Points

Business Footprint:[1]
The company caters to diverse end-user industries like Pharmaceuticals, Animal Health, Agrochemicals, Consumer Packaged Goods, Chemicals/Polymers. It has 400+ active customers with engagements with 13 out of the top 15 global pharma companies. The company holds 400+ patents jointly with clients and has a base of 6000+ scientists.

Website BSE NSE
  • Market Cap ₹ 18,983 Cr.
  • Current Price ₹ 471
  • High / Low ₹ 729 / 380
  • Stock P/E 52.5
  • Book Value ₹ 117
  • Dividend Yield 0.27 %
  • ROCE 10.0 %
  • ROE 7.74 %
  • Face Value ₹ 10.0
Edit ratios

Pros

  • Company has reduced debt.
  • Company is almost debt free.

Cons

  • Stock is trading at 4.04 times its book value
  • The company has delivered a poor sales growth of 9.45% over past five years.
  • Company has a low return on equity of 9.70% over last 3 years.
  • Dividend payout has been low at 12.7% of profits over last 3 years

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Healthcare Services Healthcare Research, Analytics & Technology

Part of BSE 500 BSE Healthcare Nifty 500 Nifty500 Shariah Nifty Smallcap 100

Edit Columns
Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026
994 716 831 792 865 726 821 877 948 799 830 834 960
678 552 614 592 565 578 613 626 638 631 653 650 676
Operating Profit 316 163 217 200 299 148 209 251 310 168 178 185 284
OPM % 32% 23% 26% 25% 35% 20% 25% 29% 33% 21% 21% 22% 30%
23 23 14 25 15 50 16 18 18 17 14 -51 14
Interest 10 6 9 6 8 7 7 7 10 6 7 6 6
Depreciation 88 89 91 94 96 92 94 92 90 95 100 97 95
Profit before tax 241 92 131 125 210 99 124 170 229 84 84 30 197
Tax % 21% 18% 22% 20% 10% 25% 22% 28% 24% 12% 21% 45% 25%
189 75 102 100 190 74 97 123 174 74 66 16 148
EPS in Rs 4.71 1.87 2.53 2.48 4.72 1.84 2.40 3.06 4.33 1.84 1.64 0.41 3.68
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
860 1,107 1,201 1,423 1,826 2,012 2,179 2,601 3,194 3,203 3,373 3,424
579 727 816 950 1,290 1,395 1,504 1,861 2,252 2,322 2,453 2,609
Operating Profit 281 380 385 473 536 617 676 741 942 881 920 815
OPM % 33% 34% 32% 33% 29% 31% 31% 28% 29% 28% 27% 24%
12 6 94 53 75 153 94 75 63 74 100 -6
Interest 8 8 18 23 32 35 28 24 45 30 31 26
Depreciation 81 97 114 131 164 219 274 310 359 369 367 387
Profit before tax 204 281 346 372 414 516 467 482 601 557 622 395
Tax % 14% 14% 17% 18% 20% 20% 14% 18% 21% 16% 25% 23%
175 241 287 305 331 412 404 394 473 466 468 305
EPS in Rs 4.38 6.02 7.18 7.63 8.27 10.29 10.09 9.83 11.78 11.60 11.63 7.57
Dividend Payout % 239% 8% 7% 7% 3% 0% 0% 10% 11% 11% 11% 17%
Compounded Sales Growth
10 Years: 12%
5 Years: 9%
3 Years: 2%
TTM: 2%
Compounded Profit Growth
10 Years: 4%
5 Years: -1%
3 Years: -8%
TTM: -16%
Stock Price CAGR
10 Years: 9%
5 Years: -4%
3 Years: -12%
1 Year: -27%
Return on Equity
10 Years: 13%
5 Years: 11%
3 Years: 10%
Last Year: 8%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Equity Capital 199 200 200 200 200 400 400 401 401 402 402 403
Reserves 646 825 1,213 1,520 1,767 1,774 2,418 2,891 3,218 3,790 4,236 4,301
155 891 806 787 813 773 893 1,022 639 332 306 201
422 440 555 681 922 1,215 1,166 1,247 1,590 1,310 1,462 1,658
Total Liabilities 1,422 2,356 2,775 3,188 3,702 4,162 4,878 5,561 5,848 5,834 6,407 6,563
503 580 810 1,030 1,377 2,020 2,201 2,393 2,260 2,318 2,241 2,492
CWIP 105 237 175 155 274 234 237 346 126 760 880 536
Investments 146 277 540 158 716 777 702 1,034 941 928 1,468 1,564
667 1,262 1,249 1,845 1,336 1,132 1,737 1,787 2,521 1,829 1,818 1,971
Total Assets 1,422 2,356 2,775 3,188 3,702 4,162 4,878 5,561 5,848 5,834 6,407 6,563

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
18 308 398 446 630 677 698 582 838 913 1,114 831
16 -753 -470 -350 -646 -424 -629 -611 -685 -383 -810 -784
-10 716 -81 -79 -72 -226 58 -31 -340 -536 -136 -178
Net Cash Flow 24 272 -153 17 -88 28 127 -60 -187 -6 167 -131
Free Cash Flow -178 16 92 82 46 34 252 107 305 568 736 544
CFO/OP 22% 92% 123% 111% 135% 127% 116% 93% 103% 115% 132% 107%

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Debtor Days 76 61 60 68 68 72 57 71 55 49 51 46
Inventory Days 59 44 37 82 30 18 41 87 141 95 62 60
Days Payable 106 87 116 194 154 157 166 115 110 104 143 136
Cash Conversion Cycle 29 18 -19 -44 -56 -67 -68 44 86 41 -30 -30
Working Capital Days -64 -65 -44 -48 -103 -172 -65 -43 21 -30 -59 -28
ROCE % 23% 20% 18% 16% 17% 17% 14% 13% 15% 13% 13% 10%

Insights

In beta
Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Total Headcount
Number

Log in to view insights

Please log in to see hidden values.

Login
Laboratory and Infrastructure Area
Million sq. ft.
Number of Active Clients
Number
Number of Scientists
Number
Revenue Mix - Manufacturing (CDMO)
Percentage
Revenue Mix - Research Services (CRO)
Percentage
Patents held with clients
Number
Single-use Bioreactor Capacity (Large Molecules)
Litres

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

4 Recently
Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
54.80% 54.79% 54.79% 54.79% 54.72% 54.72% 52.74% 52.74% 52.68% 52.68% 52.68% 52.68%
23.19% 23.55% 21.20% 20.92% 20.64% 20.72% 20.65% 19.47% 16.51% 16.31% 14.96% 13.91%
11.20% 11.70% 14.63% 15.80% 16.78% 17.49% 19.52% 21.50% 24.05% 24.62% 25.83% 26.44%
10.23% 9.47% 9.07% 8.18% 7.44% 6.74% 6.79% 5.99% 6.45% 6.08% 6.22% 6.69%
0.60% 0.48% 0.32% 0.31% 0.43% 0.34% 0.29% 0.29% 0.31% 0.30% 0.29% 0.29%
No. of Shareholders 1,25,4551,25,9921,21,8801,15,8501,20,0181,07,3381,28,8061,25,0901,42,3101,36,0611,31,7501,35,605

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

DRHP

Credit ratings

Concalls